1. A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). NLM Identifier: NCT00664326. Available from URL:
http://www.clinicaltrials.gov/ct2/show/NCT00664326?term=regorafenib+renal+cell&rank=1
.
2. A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma (METEOR). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). NLM Identifier: NCT01865747. Available from URL:
http://www.clinicaltrials.gov/ct2/show/NCT01865747?term=cabozantinib+renal&rank=1
.
3. A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). NLM Identifier: NCT01136733. Available from URL:
http://www.clinicaltrials.gov/ct2/show/NCT01136733?term=NCT01136733&rank=1
.
4. A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma (TIVO-1). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). NLM Identifier: NCT01030783. Available from URL
http://www.clinicaltrials.gov/ct2/show/NCT01030783?term=NCT01030783&rank=1
.
5. An Open-label, Randomized, Multi-center, Phase III Study to Compare the Safety and Efficacy of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma After Failure of Anti-angiogenic (VEGF-targeted and mTOR Inhibitor) Therapies. ESMO (2013).